A phase i study of vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 8, 2010, Pages 1285-1288

  Blackhall, Fiona H ^a   Obrien, Mary ^b   Schmid, Peter ^b   Nicolson, Marianne ^c   Taylor, Paul ^d   Milenkova, Tsveta ^e   Kennedy, Sarah J ^e   Thatcher, Nick ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d WYTHENSHAWE HOSPITAL   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Chemotherapy; Combination; NSCLC; Pharmacokinetics; Vandetanib

Indexed keywords

CISPLATIN; DRUG METABOLITE; GEMCITABINE; NAVELBINE; PLATINUM; VANDETANIB;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOKALEMIA; INGUINAL PAIN; INSOMNIA; LETHARGY; LOWER RESPIRATORY TRACT INFECTION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL ISCHEMIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; VEIN THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PIPERIDINES; QUINAZOLINES; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; VINBLASTINE;

EID: 77955123488     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e3a2d1     Document Type: Article

References (14)

1. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-4655.
2. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-7290.
3. Natale RB, Thongprasert S, Greco FA, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009;27(15 Suppl):Abstract 8009.
4. de Boer R, Arrieta O, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). J Clin Oncol 2009;27(15 Suppl):Abstract 8010.
5. Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 2009;27(18 Suppl):Abstract CRA8003.
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
7. Togna GI, Togna AR, Franconi M, et al. Cisplatin triggers platelet activation. Thromb Res 2000;99:503-509.
8. Ma L, Francia G, Viloria-Petit A, et al. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 2005;65:5365-5373.
9. de Boer R, Arrieta O, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). Presented at the 2009 American Society of Clinical Oncology (ASCO), Orlando, FL May 29-June 2, 2009.
10. Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). Presented at the 2009 American Society of Clinical Oncology (ASCO), Orlando, FL, May 29-June 2, 2009.
11. Gamelin E, Allain P, Maillart P, et al. Long-term pharmacokinetic behavior of platinum after cisplatin administration. Cancer Chemother Pharmacol 1995;37:97-102.
12. Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005;167:1477-1484.
13. Papadimitrakopoulou V, Frank SJ, Blumenschein GR, et al. Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2009;27(15 Suppl):Abstract 6016.
14. Heymach JV, Paz-Ares L, de Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:5407-5415.